1. Generics Bulletin
  2. >>Business

Biocon Closes $3bn Deal For Viatris Biosimilars

Cites ‘Historic Inflection Point’ For Biocon Biologics As Viatris Also Begins Transformation

 
• By Dave Wallace

Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.

$3 billion icon blue
The deal value comprises $2bn cash upfront and a $1bn share issue • Source: Shutterstock

Biocon Biologics has achieved a major milestone by closing its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what Biocon management described as a “historic inflection point” for the Indian biosimilars player.

It comes after Biocon Biologics and Viatris obtained all necessary approvals from global regulators including the US Federal Trade Commission, the Competition Commission of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.